Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

START Trial Will Show Whether Therapeutic Vaccine Stimuvax Has Potential To Extend Lung Cancer Survival Beyond Five Years
Of all cancers, non-small cell lung cancer (NSCLC) represents one of the greatest unmet needs for an effective and life-prolonging treatment. The condition, which accounts for 85 per cent of all lung cancers - roughly 1.4 million worldwide each year - is rarely diagnosed at its earliest and most potentially curable stage when it is amenable to surgical resection. Most patients are diagnosed when the tumour has already advanced to stage III, where it has invaded the chest tissues or mediastinal lymph nodes and is inoperable, or to stage IV where it has spread to other organ sites. Around 30 per cent are diagnosed at stage III and 40 per cent at stage IV. Both stages carry a poor prognosis. From stage III, and following chemo and radiotherapy treatment, median survival has been at best only between 13 and 18 months.
generic viagra online
Mersana Reports Preliminary Phase 1 Results Of XMT-1001 In Patients With Advanced Solid Tumors
Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana"s biodegradable polymer platform, Fleximer(R).
News of the day
Celiac Disease Four Times More Common Than In 1950s
Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology.
Mental Health

The UJI Is Working To Develop A Digital Analysis System Of Multispectral Images That Allows Melanoma To Be Distinguished From Other Kinds Of Diseases

The Computer Vision research group at the Universitat Jaume I of CastellÃö is working with the Hospitals Consortium of CastellÃö to develop a digital analysis system of multispectral images to help physicians distinguish melanoma from other kinds of skin diseases. A cooperation agreement has been signed by UJI, the University-Business Foundation and the CastellÃö Provincial Hospital Foundation to implement this project. The research project entitled "Characterisation of melanoma through spectral imaging" will be carried out by physicians of the Oncology, Surgery and Dermatology Departments of the CastellÃö Provincial Hospital, led by surgeon Enrique BoldÃö and technicians from the Department of Computer Languages and Systems, directed by Professor Filiberto Pla. They will create a database with multispectral images of melanomas and will select the multispectral bands for their subsequent study and classification. The first stage includes the analysis of dermoscopic images of melanomas and benign lesions to determine whether the distinctive features might be identified by a computer. The second stage includes a dermoscopy during the patient"s visit to the dermatologist and a spectrography during visits to oncology surgeons to later compare both results and check them against the pathologic anatomy. The objective is to determine what substances can be applied on the melanoma to facilitate its spectrographic analysis, and what multispectral features help diagnose melanomas. All this is carried out with the aim of creating an application software to improve medical assistance. According to Dr. BoldÃö, melanoma is the most widespread tumour worldwide and, in the early nineties, CastellÃö was the Spanish province with the highest mortality rate among the masculine population. The CastellÃö Provincial Hospital has developed innovative techniques to treat melanomas such as surgery guided by radioisotopes and the sentry node, as well as the melanoma vaccination prepared with the patient"s own tumour cells. Furthermore, the Consortium of Hospitals and its Foundation are conducting a study in collaboration with the Spanish Centre of Oncology Research (CNIO) to know the genetic characteristics of patients from CastellÃö with melanoma. This study will enhance the effectiveness of treatments as it will no longer depend on data of patients from other countries or other parts of Spain. Universitat Jaume I


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009